Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis

Diabetology & Metabolic Syndrome

Review

Hyder Mirghani¹  Ibrahim Altedlawi Albalawi² 

[1] Department of Internal Medicine, Faculty of Medicine, University of Tabuk, PO Box 3378, 51941, Tabuk, Saudi Arabia;Department of Surgery, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia;

关键词: Bariatric surgery;    Metabolic surgery;    Diabetes remission;    Usual care;    Lifestyles;   

DOI  :  10.1186/s13098-023-01001-4

 received in 2023-01-31, accepted in 2023-02-17,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundBariatric surgery is superior to usual care for diabetes remission. Previous meta-analyses were limited by pooling observational and randomized trials, using various definitions of diabetes remission, and not controlling for various diabetes medications. The current meta-analysis aimed to compare bariatric surgery and usual care regarding the same.MethodsWe searched PubMed MEDLINE, Web of Science, SCOPUS, and Cochrane Library for relevant articles from the date of the first inception up to February 2023. The keywords diabetes remission, Bariatric surgery, metabolic surgery, lifestyles, usual care, GLIP-1 agonists, insulin use, gastric banding, biliopancreatic diversion, sleeve gastrectomy, and Roux-en-Y gastric bypass, were used. A datasheet was used to extract the relevant data.ResultsDiabetes remission (complete and prolonged) was higher among bariatric surgeries compared to usual care, odd ratio, 0.06, 95 CI, 0.02–0.25 and 0.12, 95 CI, 0.02–0.72, respectively. bariatric surgery patients were younger, had higher HbA1c, odd ratio, − 3.13, 95 CI, − 3.71 to 2.54, and 0.25, 95 CI, 0.02–0.48, respectively, insulin use was higher, and glucagon-like peptide agonists use was lower among bariatric surgery patients, odd ratio, 0.49, 95% CI, 0.24–0.97, and 3.06, 95% CI, 1.44–6.53, respectively.ConclusionBariatric surgery was better than usual care in diabetes remission. Bariatric surgery patients were younger, had higher HbA1c, and received more insulin and lower GLP-1 agonists. No differences were evident regarding body mass index and the duration of diabetes. Further trials comparing the new anti-diabetic medications and different forms of bariatric surgery and controlling for the level of exercise and diet are recommended.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 10

Fig. 8

Fig. 6

Fig. 2

Fig. 4

Fig. 1

40517_2023_248_Article_IEq13.gif